Thrombotic thrombocytopenia After Sinopharm BBIBP‐CorV COVID‐19 vaccination

Rezvan Hosseinzadeh, Mohammad Barary, Hamed Mehdinezhad, Terence T. Sio, Florian Länger, Sahar Khosravi

Research and Practice in Thrombosis and Haemostasis · 2022 · 22 citations · 10 references

DOIFull text

Open access

Concepts

Abstract

Background: Severe side effects after vaccination with coronavirus disease 2019 (COVID-19) vaccines are rare but can be fatal. To date, vaccine-induced immune thrombotic thrombocytopenia (VITT) cases have been reported after injection of mRNA and adenoviral vectors COVID-19 vaccines. Here, we report the second suspected case of VITT after vaccination with the Sinopharm vaccine, an inactive vaccine. Key Clinical Question: The Key Clinical Question was to determine whether inactivated COVID-19 vaccines could induce VITT and how to diagnose and treat such cases. Clinical Approach and Conclusions: Our patient developed deteriorating symptoms the day after vaccination and was admitted to the emergency department on day 5 after vaccination. After performing laboratory analysis, thrombosis with thrombocytopenia was suggested, further confirmed by highly positive anti-heparin-platelet factor 4 antibodies assay and color Doppler ultrasonography. He was then treated with high-dose intravenous immunoglobulin, corticosteroid, and nonheparin anticoagulant.

References

10